Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Quantification of Respiratory-induced Prostate Motion

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2009 by Oregon Health and Science University.
Recruitment status was  Active, not recruiting
Information provided by:
Oregon Health and Science University Identifier:
First received: September 19, 2009
Last updated: September 21, 2009
Last verified: September 2009

Patient anatomy and position during the course of radiation therapy can vary from those used for treatment planning; a function of patient movement, uncertainty in positioning system, and organ motion. Traditionally, treatment margins are designed to compensate for interfraction prostate setup variability. This approach has the potential to lower the overall effectiveness of treatment because the prostate gland is a continuously moving target whose motion cannot be accurately accounted for solely on the basis of interfraction movement. More recently, the dosimetric relevance of intra-fraction prostate motion has been recognized, and may be compensated for by continuous real-time adaptive radiation therapy afforded by the Calypso 4D Localization System™. In the current study, the investigators propose to characterize intrafraction prostate motion. The investigators hypothesize that intrafraction prostate motion is correlated with respiratory motion.

Prostate Cancer

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Pilot Study on the Quantification of Respiratory-induced Prostate Motion During Radiation Therapy Using Continuous Real-time Tracking

Further study details as provided by Oregon Health and Science University:

Enrollment: 5
Study Start Date: September 2009
Estimated Study Completion Date: September 2010
Estimated Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Localized prostate cancer patients undergoing intensity-modulated radiation therapy.


Inclusion Criteria:

  • Histologically confirmed stage I-III adenocarcinoma of the prostate gland
  • Age > 18 years. Males of all races and ethnic groups
  • Scheduled to receive radiation for definitive therapy
  • Three (3) electromagnetic transponders implanted into prostate gland

Exclusion Criteria:

  • Does not satisfy inclusion criteria
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00980993

United States, Oregon
Oregon Health and Science University
Portland, Oregon, United States, 97239
Sponsors and Collaborators
Oregon Health and Science University
Principal Investigator: James A. Tanyi, Ph.D. Oregon Health and Science University
  More Information

Additional Information:
No publications provided

Responsible Party: James A. Tanyi, Ph.D., Oregon Health and Science University Identifier: NCT00980993     History of Changes
Other Study ID Numbers: OHSU IRB00005606
Study First Received: September 19, 2009
Last Updated: September 21, 2009
Health Authority: United States: Institutional Review Board

Keywords provided by Oregon Health and Science University:

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms by Site
Prostatic Diseases
Urogenital Neoplasms processed this record on November 20, 2014